Teva Pharmaceutical Industries (NYSE:TEVA) Upgraded by StockNews.com to Strong-Buy

StockNews.com upgraded shares of Teva Pharmaceutical Industries (NYSE:TEVA) from a buy rating to a strong-buy rating in a research report sent to investors on Thursday morning.

A number of other brokerages have also recently commented on TEVA. Piper Sandler restated an overweight rating and set a $20.00 target price (up from $19.00) on shares of Teva Pharmaceutical Industries in a report on Monday, May 13th. UBS Group raised their price objective on shares of Teva Pharmaceutical Industries from $22.00 to $24.00 and gave the company a buy rating in a research note on Wednesday, July 10th. Jefferies Financial Group raised their price objective on shares of Teva Pharmaceutical Industries from $19.00 to $23.00 and gave the company a buy rating in a research note on Thursday, June 27th. Argus raised shares of Teva Pharmaceutical Industries from a hold rating to a buy rating and set a $20.00 price objective for the company in a research note on Wednesday, July 10th. Finally, Barclays raised their price objective on shares of Teva Pharmaceutical Industries from $20.00 to $21.00 and gave the company an overweight rating in a research note on Wednesday, June 5th. Two equities research analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat, Teva Pharmaceutical Industries currently has an average rating of Moderate Buy and a consensus target price of $18.56.

Teva Pharmaceutical Industries Price Performance

NYSE:TEVA opened at $17.10 on Thursday. Teva Pharmaceutical Industries has a 52 week low of $8.06 and a 52 week high of $17.69. The company has a quick ratio of 0.61, a current ratio of 0.89 and a debt-to-equity ratio of 2.20. The company has a market capitalization of $19.37 billion, a P/E ratio of -41.71, a P/E/G ratio of 1.50 and a beta of 0.90. The stock’s fifty day moving average is $16.76 and its two-hundred day moving average is $14.56.

Teva Pharmaceutical Industries (NYSE:TEVA) last posted its earnings results on Wednesday, May 8th. The company reported $0.46 EPS for the quarter, missing analysts’ consensus estimates of $0.49 by ($0.03). Teva Pharmaceutical Industries had a negative net margin of 2.88% and a positive return on equity of 37.33%. The business had revenue of $3.82 billion during the quarter, compared to analysts’ expectations of $3.70 billion. Equities analysts expect that Teva Pharmaceutical Industries will post 2.32 EPS for the current year.

Insider Activity

In other news, insider Vikki L. Conway sold 15,219 shares of Teva Pharmaceutical Industries stock in a transaction on Monday, May 13th. The shares were sold at an average price of $16.74, for a total value of $254,766.06. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. In other Teva Pharmaceutical Industries news, insider Vikki L. Conway sold 15,219 shares of the business’s stock in a transaction on Monday, May 13th. The shares were sold at an average price of $16.74, for a total value of $254,766.06. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, Director Roberto Mignone sold 519,000 shares of the business’s stock in a transaction on Tuesday, June 18th. The shares were sold at an average price of $17.03, for a total transaction of $8,838,570.00. Following the completion of the transaction, the director now directly owns 981,000 shares in the company, valued at $16,706,430. The disclosure for this sale can be found here. Insiders have sold 549,719 shares of company stock valued at $9,353,736 in the last ninety days. 0.55% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Teva Pharmaceutical Industries

Institutional investors have recently bought and sold shares of the company. Sequoia Financial Advisors LLC boosted its position in shares of Teva Pharmaceutical Industries by 0.7% during the 2nd quarter. Sequoia Financial Advisors LLC now owns 111,575 shares of the company’s stock worth $1,813,000 after purchasing an additional 826 shares in the last quarter. Edmond DE Rothschild Holding S.A. boosted its position in shares of Teva Pharmaceutical Industries by 4.0% during the 1st quarter. Edmond DE Rothschild Holding S.A. now owns 24,495 shares of the company’s stock worth $346,000 after purchasing an additional 947 shares in the last quarter. Desjardins Global Asset Management Inc. boosted its position in shares of Teva Pharmaceutical Industries by 15.2% during the 4th quarter. Desjardins Global Asset Management Inc. now owns 8,123 shares of the company’s stock worth $85,000 after purchasing an additional 1,070 shares in the last quarter. Oppenheimer & Co. Inc. boosted its position in shares of Teva Pharmaceutical Industries by 9.6% during the 1st quarter. Oppenheimer & Co. Inc. now owns 13,522 shares of the company’s stock worth $191,000 after purchasing an additional 1,180 shares in the last quarter. Finally, QRG Capital Management Inc. boosted its position in shares of Teva Pharmaceutical Industries by 0.8% during the 2nd quarter. QRG Capital Management Inc. now owns 144,938 shares of the company’s stock worth $2,355,000 after purchasing an additional 1,191 shares in the last quarter. 54.05% of the stock is owned by institutional investors and hedge funds.

Teva Pharmaceutical Industries Company Profile

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.